Standard surgical treatment in pancreatic cancer by Wagner, M. et al.
Annals of Oncology 10 Suppl. 4: S247-S251,1999.
© 1999 KUtwer Academic Publishers. Printed in the Netherlands.
Review.
Standard surgical treatment in pancreatic cancer
M. Wagner, N. Dikopoulos, C. Kulli, H. Friess & M. W. Buchler
Department of Visceral and Transplantation Surgery of the University of Bern, 3010 Bem, Switzerland
Summary
Pancreatic cancer is the third leading neoplasm of the
gastrointestinal system and has a dismal prognosis. The majority of
patients are no more suitable for resection at time of diagnosis due
to early development of distant metastases or major infiltrations of
adjacent structures. However, due to the resistance of pancreatic
cancers against chemoradiation, curative resection represents the
only therapy with a potential for cure. For the surgical treatment of
pancreatic head cancer, the classical Whipple operation is still the
standard procedure but during the last two decades, pylorus-
preserving duodenopancreatectomy has been evolved as a more
conservative procedure in order to omit the consequences of partial
gastrectomy. For cancer of the pancreatic body and tail, distal
pancreatectomy or total pancreatectomy represent the current
standard treatment. More radical methods like regional
pancreatectomy and resection with extended lymph node dissection
have failed so far to demonstrate any improvements in long-term
survival compared to the standard types of resection. To further
improve the treatment of pancreatic cancer, prospectively
randomised trials are needed to compare these extended surgical
procedures with the standard types of resection.
Key words: classical Whipple operation, extended lymph node
dissection, left resection, mortality, morbidity, long-term outcome,
pancreatic cancer, pylorus-preserving duodenopancreatectomy,
regional pancreatectomy, total pancreatectomy
Introduction
Pancreatic cancer constitutes currently the third leading
neoplasm of the gastrointestinal system and is characterised
by an aggressive growth and an extremely poor prognosis.,
therefore making pancreatic cancer the fourth leading cause
of cancer-related death in the Western world [1]. Since
current conservative oncological therapies have failed to
show any long-term success, curative resection remains the
only therapy with a potential for cure [ 1 ]. During the last two
decades, the risks of pancreatic resections have decreased
considerably and a mortality rate of under 5% after
pancreatoduodenectomy is nowadays considered a standard
achievement in experienced centres [2, 3]. During the same
time period, a steady increase in the rate of resection can be
observed so that some centres report now a resectability of
over 50% [2]. Despite these significant advances in
pancreatic surgery, improvements in long-term survival are
less obvious since most patients suffer from the early
occurrence of local recurrence or distant metastases even
after curative resection. An recent survey under surgeons in
the United States demonstrated an overall long-term survival
rate of under 10% with a median survival period of 18 month
after resection for pancreatic cancer and other studies from
experienced centres have reported similar results [4-6].
The reasons for this biological aggressiveness are not
known. However recent molecular-biological studies have
shown that pancreatic cancers harbour a variety of genetic
alterations and overexpress numerous growth factors and
their receptors [7]. Although the biological significance of
these multiple growth factor overexpression is currently not
fully understood, experimental studies have shown that
inhibition of the signaling pathway downstream of the
receptor may inhibit pancreatic cancer growth [8, 9]. It may
be hoped that a better understanding of the biological
relevance of the molecular alterations of pancreatic cancer
will lead to further improvements of current therapies and to
the development of new treatment modalities in the near
future such as gene therapy approaches for example [10].
Standard surgical procedures for the treatment of
pancreatic cancer
Standard Whipple resection
It was the pioneering work of Allen O. Whipple to
standardise the procedure of partial pancreatoduodenectomy
which in honour of this great surgeon bears now his name
[2]. Since 60-70% of all pancreatic cancers are located in the
head region, the Whipple procedure is still considered the
standard surgical procedure by most surgeons. The operation
consists of resection of the pancreatic head together with the
duodenum, the distal half or two thirds of the stomach
together with the right half of the great omentum, the
gallbladder with the common bile duct and the peripancreatic
lymph nodes [11]. Reconstruction is performed by a
pancreato-jejunostomy as favoured by most surgeons or by
a pancreato-gastrostomy [2]. Although, the mortality has
decreased to a rate of under 5% in experienced centres [2,3],
postoperative morbidity still remains considerably with the
occurrence of pancreatic fistula and severe bleeding being
the most serious ones [12]. However, the administration of
synthetic somatostatin-analogues as a perioperative
antisecretory regimen has lead to a significantly reduction of
pancreatic fistulas in two randomised studies [13, 14]. In
contrast to these improvements in perioperative morbidity
and mortality, increases in long-term survival are less
obvious. Although, some authors showed a 5-year survival
rate of 15-28% [2, 15, 16], most institutions continue to
report a survival rate of no more than 10% with an average
survival time of 12-18 months [4, 17, 18]. Significantly
better is the prognosis for patients resected with an early
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Table 7. Mortality and 5-year survival after classical Whipple operation
Author
Condie et al
Funovics et al
Lygidakis et al
Trede et al
Cameron et al
Roder et al
Beger et al
Baumel et al
Sperti et al
Chou et al
Van Berge Henderson et al
Bern
year
1989
1989
1989
1990
1991
1992
1994
1994
1996
1996
1997
1998
N
13
100
111
133
52
31
101
555
113
93
100
52
mortality
31%
13%
2%
2%
9%
2%
4%
8%
5%
8%
6%
3.8%
survival
7.7%
5%
24%
19%
3%
9%
15%
12%
cancer stage (stage I according to the UICC classification),
although few patients will present with these stage at time of
diagnosis [16, 19, 20]. (Studies summarized in Table 1). .
The pylorus-preserving pancreatic head resection
The pylorus-preserving pancreatic head resection represents
a more conservative alternative to the classical Whipple
procedure and was developed for the treatment of tumours
of the papilla of Vater to omit the side effects of partial
gastrectomy [21]. The procedure was popularised by
Traverso and Longmire and many surgeons have now
adopted the procedure for the treatment of chronic
pancreatitis and pancreatic cancer as well [2]. Technically,
the duodenum is divided 2-3 cm distal the pylorus region, the
pylorus together with its neurovascular supply is preserved
and reconstruction is performed by a end-to-side
duodenojejunostomy [2]. The remaining steps of the
operation are identical with the classical Whipple-procedure.
Doubts have been raised as to the radicality of the pylorus-
preserving procedure for pancreatic cancer [2]. However,
histopathological studies from 140 operative specimen from
patients with pancreatic head cancer showed no tumour
infiltration of the pylorus region or the lymph nodes along
the major and minor curvatures of the stomach [22].
Analysing comparable tumour stages, long-term survival
after the pylorus-preserving technique seems to show no
significant deviation from the results after classical
duodenopancreatectomy with the exception of one
retrospective study on a small patient sample which reported
an advantage for the classic Whipple procedure in patients
with stage HI disease [2, 23, 24]. Today, preservation of the
pylorus is now widely accepted as a suitable alternative to
the classic Whipple procedure for all stages of pancreatic
cancer [25].
Another point of debate remains the effect of pylorus-
preserving Whipple resection on gastrointestinal function
since some authors reported a higher incidence of delayed
gastric emptying after pylorus-preserving resection while
others could not [2, 23, 26]. Commonly, delayed gastric
emptying is a temporary occurrence and gastric function will
normalise within a period of 2-4 weeks postoperatively in the
majority of patients [27]. A plausible explanation for this
temporary delay in gastric function may be the formation of
an anastomotic oedema in the initial postoperative period
which could be aggravated by a disturbance in neurovascular
supply. In a recent study, the presence of intraabdominal
complications was detected as a major risk factor for delayed
gastric emptying independently of the performed type of
resection [26]. This observation goes along with our own
experience in 112 consecutive pancreatic head resections for
pancreatic cancer. However, controlled randomised trials
comparing long term survival, gastrointestinal function and
quality of life after classical Whipple and pylorus-preserving
resection are needed in order to evaluate these two
procedures in the future.
Another advantage of the more conservative pylorus-
preserving technique concerns postoperative weight gain
which seems to favour the preservation of the pylorus [24,
28]. However, data from randomised studies are still lacking
to prove this hypothesis. (Studies summarized in Table 2)
Resection of cancer of the pancreatic body and tail
In about 30% of cases, pancreatic cancers are located in the
body and tail of the pancreas. Due to their lack of symptoms,
these tumors are typically diagnosed in advanced tumour
stages and therefore only a minority of patients are suitable
for resection. [29]. If only the pancreatic tail is involved,
pancreatic left resection can be performed. Therefore the
greater curvature of the stomach is mobilised as well as the
left colon flexure. The splenic artery is lighted and the
pancreas is dissected near the body region with a sufficient
large resection margin to the tumour. The distal pancreas is
then removed together with the peripancreatic lymph nodes
and the spleen to ensure radical resection. Median survival
period was given by 13 month in a recent study while others
report a 3-year or 5-year survival rate of 19% and 16.6% for
localised cancers respectively [29-31].
If the cancer infiltrates the pancreatic body or if there is
multi-locular disease, total pancreatectomy may be indicated
[32]. The technique is formally identical to a Whipple
resection, however the pancreas is fully mobilised and
resected together with the spleen and the lymph nodes
around the pancreas as well as along the left gastric artery,
the splenic artery and the celiac trunc. Reconstruction is
simplified and consists of a hepato-jejunostomy and a
gastrpjejunostomy. If the pylorus region is not infiltrated by
tumour masses, we prefer to perform a pylorus-preserving
total pancreatectomy similar to the pylorus-preserving
Whipple resection. Total pancreatectomy was first described
by Ross and Porter in 1954 in order to decrease the
substantial mortality and morbidity of pancreatic leakage
after pancreatic head resection and to improve long-term
survival [2]. However, most surgeons experienced no
significant advantage in long-term survival when compared
Table 2. Mortality and 5-year survival after pylorus-preserving Whipple
operation.
Author
Grace etal
Braasch et al
Klinkenbijl et al
Roder etal
Biichler et a]
Kozuschek et al
Mosca et al
Tsao et al
Van Berge Henderson et al
Yeo et al
Bern
year
1986
1986
1992
1992
1993
1993
1994
1994
1997
1997
1998
N
13
14
' 25
22
19
24
76
22
100
650
59
mortality
4%
2%
2%
2%
5%
8%
7.5%
2%
1%
1.9%
3.4%
survival
25%
0%
9%
19%
12%
7%
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with the results after a standard Whipple procedure [33].
Furthermore, early total resection of the pancreas was
compromised by a substantial mortality of up to 37% and the
consequences of both exocrine and endocrine depression of
pancreatic function [33,34]. Thus, some authors reported the
occurrence of lethal hypoglycaemia due to unmanageable
diabetes mellitus [33]. With the advances in pancreatic
surgery and the development of antisecretory regimens,
pancreatic anastomosis can now be performed safely and
total pancreatectomy is no longer indicated today for
localised tumours in the pancreatic head [33].
More radical surgical procedures
Despite marked advances in pancreatic surgery, the majority
of patients suffer from distant metastases or local tumour
recurrence a short period after resection. In an effort to
improve long-term results after pancreatic resection, more
radical procedures have been developed. At present, these
techniques are not accepted as standard operations and are
therefore performed only by few surgeons in the Western
world as well as in Japan. To evaluate the indications and
impact on survival of these procedures, additional studies in
the near future are urgently needed.
Subtotal pancreatectomy
This procedure is based on the observation that the
pancreatic tail and its lymph nodes are rarely affected by
pancreatic cancer [35]. Utilising this fact, Gall et al.
developed subtotal pancreatectomy in order to allow wider
resection margins in combination with a more complete
lymph node dissection and to omit the metabolic side effects
of total pancreatectomy [36]. The operation is identical to a
standard Whipple operation but only the very last 5 cm of
the pancreatic tail are preserved and the pancreatic remnant
is then oversutured so that reconstruction comprises a
hepaticojejunostomy and a gastroenterostomy.
The procedure was adopted only by few surgeons. The
reported mortality and morbidity equals that of a standard
Whipple resection [36]. A major drawback of the procedure
is the high occurrence of pancreatic fistula in up to 20% of
cases [37]. Long-term results are sparse and the impact of
this alternative procedure can therefore not clearly be
estimated. However, total pancreatectomy as a more radical
type of resection has failed to improve survival and
pancreatic anastomoses can nowadays be performed safely.
Therefore, subtotal pancreatectomy offers no advantage
versus a standard Whipple resection for cancer of the
pancreatic head.
Regional pancreatectomy
The principle of regional pancreatectomy was first
introduced by Joseph Former in 1973 in order to improve
resectability in advanced tumour stages [38]. The procedures
consists of an en bloc removal of the total or subtotal
pancreas with a 4cm soft tissue margin along with a distal
gastrectomy, duodenectomy and cholecystectomy and the
common bile duct [38]. The regional lymph nodes from the
diaphragm to the inferior mesenteric artery including the
lymph stations around the inferior mesenteric artery, the
hepatic artery, the celiac trunc, the superior mesenteric artery
and the portal vein together with the intrapancreatic segment
of the portal vein are carefully dissected [38].
Since the initial series reported a mortality of 25%, regional
pancreatectomy was rarely employed by surgeons in Europe
and North America [2]. In addition, first series did not show
any advantage in long-term survival as compared to a
standard duodenopancreatectomy [2]. However, a recent
study reported a mortality rate equally to those reported after
a classical Whipple procedure and a 5-year survival rate of
33% for tumours less than 2.5 cm in diameter [39]. To
evaluate this procedures randomised studies comparing the
results of regional pancreatectomy with those after standard
Whipple resection in patients with identical tumour stages
would be needed. At present, the procedure can not be
recommended as a standard surgical procedure.
Pancreatectomy with extended lymph node resection
Despite the advances in pancreatic surgery during the last
decades, all efforts to improve long-term survival after
radical pancreatectomy have only slightly increased the 5-
year survival rates [1]. The reasons for this persistent dismal
prognosis are on one hand diagnosis in mostly advanced
stages and on the other hand the biological aggressiveness of
these cancers [1]. Thus, around 80% of patients have
positive lymph nodes or distant metastases at time of
diagnosis [2]. Although, presence of distant metastases is
regarded as a general contraindication for surgery, lymph
nodes can be removed thus enabling curative resection
theoretically. Therefore surgeons in Japan have developed an
extended lymph node dissection, based on the principles of
regional pancreatectomy, which has now been adopted and
standardised by the Japanese Pancreatic Society as a routine
procedure for pancreatic cancer. The procedure includes
regional lymphadenectomy of the lymph stations around the
aorta and caval vene, the inferior and superior mesenteric
vene as well as the portal vene. Furthermore, the lymphatic
tissue around the hepatoduodenal ligament, the superior
mesenteric artery, the splenic artery and the celiac trunc are
totally dissected [40,41].
Applying this technique, the resection rate has gradually
increased from a mere of 20% up to 60% as reported by a
recent study [42]. With the advances in surgery and
perioperative intensive care unit management, the initially
considerable mortality has now decreased to rates similar to
those reported after a classical Whipple procedure [43,44].
In contrast to the decreasing mortality, morbidity remains
high and quality of life can severely be impaired after
extended lymph node dissection mainly due to the
occurrence of severe diarrhoea which may be caused by
autonomous denervation of the bowels [45].
Histopathological studies from specimen after extended
lymph node dissection have demonstrated positive lymph
node metastases in 78% [46]. Similar, another study has
shown that even small tumours of less than 2 cm in diameter
which do not infiltrate the organ capsule showed positive
paraaortal lymph nodes in 40% of cases [47]. The highest
prevalence of lymph node metastases are found in the
anterior and posterior pancreatoduodenal lymph nodes as
well as in the paraaortal region [48]. Despite these
interesting histopathological data which seem to confirm the
importance of extended lymph node dissection, the impact of
this strategy on long-term survival is less obvious. Studies
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Table 3. Surgical treatment of pancreatic cancer in Bern (n=238)
Procedure N Percentage
Exploration
Bypass
Double bypass
Hepatojejunostomy
Gastroenterostomy
Resection
Pylorus-preserving Whipple
Classical Whipple
Total pancreatectomy
Left resection
43
54
32
12
10
141
59
52
16
14
18
23
59
Table 4. Morbidity and mortality after pancreatic resection in Bern (n= 141)
N Percentage
Surgical morbidity
Delayed gastric emptying
Wound sepsis
Pancreatic fistula
Non-surgical morbidity
Pulmonary
Cardial
Mortality
Reoperations
42
31
5
3
32
15
8
5
6
30
22
3.5
2.1
23
11
6
3.5
4.3
from Japan reveal a 5-year survival rate for small and early
pancreatic cancers of 28-56% [16,41,49]. However, only a
minority of patients are operated with such early cancer
stages and when results for overall survival are taken into
account the results are comparable to those reported for
standard Whipple resection in Europe and the United States
[4, 16, 50-52]. Similar, several recent non-randomised
studies and one prospective randomised study could not find
a difference in survival between standard resection and
pancreatectomy with extended lymph node dissection [51,
53-55]. However, there seems to be a trend, that the
subgroup of patients with lymph node metastases have
improved survival after radical lymphadenectomy [53]. Since
at present, there is no obvious survival benefit after extended
lymph node dissection in comparison after a standard
pancreatoduodenectomy but morbidity remains considerable,
more randomised studies are needed to assess the value of
this radical procedure.
Treatment of pancreatic cancer in Bern
Between November 1993 and January 1999 238 patients
(104 women, 134 men; median age 67 of years with a range
of 36-87 years) with pancreatic cancer were treated in the
Department of Visceral and Transplantation Surgery at the
University of Bern. At the time of diagnosis 9% of patients
had stage I, 21% had stage II, 45% had stage IH and 25%
had stage IV disease according to the UICC classification.
59% of the patients (141 cases) were treated by tumour
resection, 23% had a bypass procedure and .18% underwent
surgical exploration alone. Following tumour resection,
mortality was 3.5% (5 of 141 patients) and in-hospital
surgical related morbidity was 30% with delayed gastric
emptying being the most common complication (22%)
followed by wound sepsis (3.5%). Pancreatic fistula
occurred in 1.4% of cases and were treated by a conservative
approach. Estimated 5-year survival by Kaplan-Meier in
patients in which resection was performed was 18%.
(Data summarized in Tables 3 and 4)
Conclusion
During the past decades, a considerable decrease in
perioperative mortality after pancreatic resection and a
significant increase in the rate of resection has been
achieved. Standard types of resection are the classical
Whipple resection for cancers of the pancreatic head and
distal or total pancreatectomy for cancers of the pancreatic
tail and body respectively. The pylorus-preserving pancreatic
head resection has now become an acceptable alternative to
the classical Whipple resection, although there exist no
prospectively randomised studies demonstrating the
superiority of either method. However, data from case-
control-studies seem to indicate that preservation of the
pylorus goes along with improved quality of life and a faster
regain of body weight when compared to the classical
Whipple procedure. Advances in long-term survival are less
obvious and a 5-year overall survival rate of about 10% is
still considered a standard achievement. Efforts to improve
survival by applying more radical types of resection such as
regional pancreatectomy or radical lymph node dissection
have failed to show any clear benefit so far and are
compromised by a considerable morbidity. Although,
surgery will remain most likely the primary option for cure,
prospective randomised trials are needed to compare the
value of these more radical procedures with the standard
types of resection.
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